1144103-62-7Relevant articles and documents
TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST
-
Page/Page column 12, (2009/09/07)
The present invention relates to novel synthetic toll like receptor antagonist. The present invention in particular provides compounds, methods and compositions for specifically inhibiting immune stimulation involving TLR ligands, especially TLR-4. The compounds are potentially useful in treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.